It also highlights the therapeutic potential of targeting of 5-HT1B/1D receptors in the treatment of PaCa, and opens a new avenue for biomarkers identification, and valuable new therapeutic targets for managing pancreatic cancer. This evidence concerns the gene HTR1B and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.